The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Related Posts
JPMorgan sees S&P 500 rising to 6,500 in 2025 thanks to AI and deregulation
Strategist Dubravko Lakos-Bujas set 6,500 as his 2025 target for the broad market index. That implies upside of about 8% from Tuesday’s close.
What Trump’s mass deportation plan would mean for immigrant workers and the economy
President-Elect Donald Trump says his mass deportation plan will go ahead. Hiring firms and labor economists have begun to weigh the damage.
UBS upgrades Capital One ahead of Discover Financial acquisition
Capital One Financial’s acquisition of Discover Financial Services could spell upside for both stocks in the coming months, according to UBS.